Fusion Antibodies PLC (LSE:FAB) — Stock Price
Fusion Antibodies PLC (LSE:FAB) is currently trading at GBX10.75 GBX, up 2.38% today. Over the past 52 weeks, shares have ranged between GBX9.75 and GBX19.25. This page tracks Fusion Antibodies PLC's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Fusion Antibodies PLC (FAB) market capitalisation.
Fusion Antibodies PLC (FAB) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Fusion Antibodies PLC's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Fusion Antibodies PLC Income Statement — Revenue, Profit & Earnings by Year
Fusion Antibodies PLC's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | GBX1.97 Million | GBX1.14 Million | GBX2.90 Million | GBX4.80 Million | GBX4.17 Million |
| Cost of Revenue | GBX1.53 Million | GBX1.40 Million | GBX2.70 Million | GBX3.08 Million | GBX2.85 Million |
| Gross Profit | GBX430.00K | GBX-265.00K | GBX202.00K | GBX1.72 Million | GBX1.31 Million |
| Research & Development | GBX191.00K | GBX254.00K | GBX806.00K | GBX699.00K | GBX613.00K |
| SG&A | GBX1.86 Million | GBX2.25 Million | GBX3.05 Million | GBX3.03 Million | GBX2.74 Million |
| Total Operating Expenses | GBX2.21 Million | GBX2.24 Million | GBX3.04 Million | GBX3.05 Million | GBX2.69 Million |
| Operating Income | GBX-1.78 Million | GBX-2.29 Million | GBX-2.83 Million | GBX-1.33 Million | GBX-1.38 Million |
| EBITDA | GBX-1.62 Million | GBX-2.06 Million | GBX-2.48 Million | GBX-573.00K | GBX-532.00K |
| EBIT | GBX-1.73 Million | GBX-2.28 Million | GBX-2.85 Million | GBX-1.32 Million | GBX-1.25 Million |
| Interest Expense | GBX3.00K | GBX5.00K | GBX4.00K | GBX9.00K | GBX18.00K |
| Income Before Tax | GBX-1.78 Million | GBX-2.29 Million | GBX-2.86 Million | GBX-1.33 Million | GBX-1.26 Million |
| Income Tax Expense | GBX64.00K | GBX-63.00K | GBX-263.00K | GBX-133.00K | GBX1.64 Million |
| Net Income | GBX-1.71 Million | GBX-2.23 Million | GBX-2.60 Million | GBX-1.20 Million | GBX-2.90 Million |
Fusion Antibodies PLC Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Fusion Antibodies PLC's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | GBX1.32 Million | GBX2.42 Million | GBX2.06 Million | GBX4.92 Million | GBX5.83 Million |
| Total Current Assets | GBX1.26 Million | GBX2.26 Million | GBX1.69 Million | GBX4.28 Million | GBX4.71 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX332.00K | GBX557.00K | GBX953.00K | GBX1.65 Million | GBX1.54 Million |
| Inventory | GBX269.00K | GBX460.00K | GBX539.00K | GBX585.00K | GBX480.00K |
| Property, Plant & Equipment | — | — | GBX375.00K | GBX633.00K | GBX1.12 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | GBX654.00K | GBX627.00K | GBX939.00K | GBX1.23 Million | GBX1.08 Million |
| Total Current Liabilities | GBX623.00K | GBX584.00K | GBX879.00K | GBX1.21 Million | GBX996.00K |
| Long-term Debt | — | — | — | — | — |
| Net Debt | GBX-339.00K | GBX-1.16 Million | GBX-120.00K | GBX-1.98 Million | GBX-2.46 Million |
| Total Stockholder Equity | GBX669.00K | GBX1.79 Million | GBX1.12 Million | GBX3.68 Million | GBX4.75 Million |
| Retained Earnings | GBX-11.47 Million | GBX-9.77 Million | GBX-7.56 Million | GBX-5.00 Million | GBX-3.82 Million |
Fusion Antibodies PLC Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Fusion Antibodies PLC generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-1.36 Million | GBX-1.77 Million | GBX-1.75 Million | GBX-330.00K | GBX-1.15 Million |
| Capital Expenditures | GBX10.00K | GBX2.00K | GBX114.00K | GBX258.00K | GBX365.00K |
| Free Cash Flow | GBX-1.37 Million | GBX-1.77 Million | GBX-1.87 Million | GBX-591.00K | GBX-1.52 Million |
| Investing Cash Flow | GBX-5.00K | GBX1.00K | GBX-114.00K | GBX-258.00K | GBX-365.00K |
| Financing Cash Flow | GBX529.00K | GBX2.77 Million | GBX7.00K | GBX-46.00K | GBX2.67 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | GBX35.00K | GBX86.00K | GBX35.00K | GBX21.00K | GBX19.00K |
| Depreciation | GBX105.00K | GBX220.00K | GBX372.00K | GBX751.00K | GBX714.00K |
| Change in Cash | GBX-840.00K | GBX1.00 Million | GBX-1.85 Million | GBX-637.00K | GBX1.15 Million |
Fusion Antibodies PLC Earnings History — EPS Actual vs. Analyst Estimates
Track Fusion Antibodies PLC's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Nov 18, 2025 | 0.00 | 0.00 | — |
| Sep 04, 2025 | -0.01 | 0.00 | — |
| May 28, 2025 | 0.00 | 0.00 | — |
| Nov 19, 2024 | -0.01 | 0.00 | — |
| Sep 29, 2023 | 0.00 | -4.30 | +100.00% |
| Dec 05, 2022 | -0.04 | — | — |
| Sep 01, 2022 | -0.02 | — | — |
| Dec 06, 2021 | -0.02 | — | — |